These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32678021)

  • 1. QALY-time: experts' view on the use of the quality-adjusted LIFE year in COST-effectiveness analysis in palliative care.
    Wichmann AB; Goltstein LCMJ; Obihara NJ; Berendsen MR; Van Houdenhoven M; Morrison RS; Johnston BM; Engels Y;
    BMC Health Serv Res; 2020 Jul; 20(1):659. PubMed ID: 32678021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of Quality-Adjusted Life Years in cost-effectiveness analyses in palliative care: Mapping the debate through an integrative review.
    Wichmann AB; Adang EM; Stalmeier PF; Kristanti S; Van den Block L; Vernooij-Dassen MJ; Engels Y;
    Palliat Med; 2017 Apr; 31(4):306-322. PubMed ID: 28190374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The remarkably frequent use of EQ-5D in non-economic research.
    Wang A; Rand K; Yang Z; Brooks R; Busschbach J
    Eur J Health Econ; 2022 Aug; 23(6):1007-1014. PubMed ID: 34846623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palliative care and the QALY problem.
    Hughes J
    Health Care Anal; 2005 Dec; 13(4):289-301. PubMed ID: 16435466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4.
    Scuffham PA; Whitty JA; Mitchell A; Viney R
    Pharmacoeconomics; 2008; 26(4):297-310. PubMed ID: 18370565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using qualitative methods to inform the trade-off between content validity and consistency in utility assessment: the example of type 2 diabetes and Alzheimer's disease.
    McGrath C; Rofail D; Gargon E; Abetz L
    Health Qual Life Outcomes; 2010 Feb; 8():23. PubMed ID: 20152041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is a QALY still a QALY at the end of life?
    Round J
    J Health Econ; 2012 May; 31(3):521-7. PubMed ID: 22591713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EQ-5D Quality-of-Life Analysis and Cost-Effectiveness After Skull Base Meningioma Resection.
    Karsy M; Jensen MR; Guan J; Ravindra VM; Bisson EF; Couldwell WT
    Neurosurgery; 2019 Sep; 85(3):E543-E552. PubMed ID: 30869135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palliative care for the terminally ill in America: the consideration of QALYs, costs, and ethical issues.
    Yang YT; Mahon MM
    Med Health Care Philos; 2012 Nov; 15(4):411-6. PubMed ID: 22071573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early versus deferred endovenous ablation of superficial venous reflux in patients with venous ulceration: the EVRA RCT.
    Gohel MS; Heatley F; Liu X; Bradbury A; Bulbulia R; Cullum N; Epstein DM; Nyamekye I; Poskitt KR; Renton S; Warwick J; Davies AH
    Health Technol Assess; 2019 May; 23(24):1-96. PubMed ID: 31140402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness and cost-utility of high-dose palliative radiotherapy for advanced non-small-cell lung cancer.
    Coy P; Schaafsma J; Schofield JA
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1025-33. PubMed ID: 11072159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unchained melody: revisiting the estimation of SF-6D values.
    Craig BM
    Eur J Health Econ; 2016 Sep; 17(7):865-73. PubMed ID: 26359242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeled cost-effectiveness of transforaminal lumbar interbody fusion compared with posterolateral fusion for spondylolisthesis using N(2)QOD data.
    Carreon LY; Glassman SD; Ghogawala Z; Mummaneni PV; McGirt MJ; Asher AL
    J Neurosurg Spine; 2016 Jun; 24(6):916-21. PubMed ID: 26895529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments.
    Yang F; Devlin N; Luo N
    Eur J Health Econ; 2019 Feb; 20(1):99-105. PubMed ID: 29948432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the relative value of health and social care related quality of life using a discrete choice experiment.
    Mulhern B; Norman R; De Abreu Lourenco R; Malley J; Street D; Viney R
    Soc Sci Med; 2019 Jul; 233():28-37. PubMed ID: 31153085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives of Patients With Cancer on the Quality-Adjusted Life Year as a Measure of Value in Healthcare.
    Franklin EF; Nichols HM; Charap E; Buzaglo JS; Zaleta AK; House L
    Value Health; 2019 Apr; 22(4):474-481. PubMed ID: 30975399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of lumbar fenestration surgery in the Japanese universal health insurance system.
    Fujimori T; Miwa T; Iwasaki M; Oda T
    J Orthop Sci; 2018 Nov; 23(6):889-894. PubMed ID: 30075994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
    Beresniak A; Dupont D
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.